PEPTIDE CORTEXThe library
← The library

Tesamorelin

Egrifta SV/WRGH Axis
Evidence grade
AFDA-approved Rx (labeled use)
Cardiovascular · 0–5 · separate axis
3
Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeGH axis / Body composition
MechanismGHRH analog: stimulates endogenous GH; reduces visceral adipose tissue in HIV lipodystrophy
EffectsSignals the GH axis; can affect body composition, fluid retention, and glucose
DosingEgrifta SV: 1.4 mg SC once daily; Egrifta WR: 1.28 mg SC once daily
Bottom lineStrongest data when used for its labeled indication under clinician guidance.
Protocols · as published4 sourced
FDA labelEgrifta WR (HIV lipodystrophy abdominal fat)
RouteSubcutaneous injection into the abdomen, rotating sites
FrequencyOnce daily
Starting1.28 mg once daily; no titration
EscalationNone
Target1.28 mg once daily
Maximum1.28 mg daily

Indication is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy only. Reconstitute 1 vial with 1.3 mL diluent (8 mg/mL); discard unused solution 7 days after mixing.

FDA labelEgrifta SV (HIV lipodystrophy abdominal fat)
RouteSubcutaneous injection into the abdomen, rotating sites
FrequencyOnce daily
Starting1.4 mg (0.35 mL of reconstituted solution) once daily; no titration
EscalationNone
Target1.4 mg once daily

Reconstitute the 2 mg vial with 0.5 mL diluent.

Clinical trialPhase 3 (Falutz, NEJM 2007)
RouteSubcutaneous injection
FrequencyOnce daily, 26 weeks
Starting2 mg daily
EscalationNone
Target2 mg daily (original formulation, before SV and WR)

HIV patients with abdominal fat accumulation. VAT reduction reported at about 15% (from a search summary; paper not read directly).

Community protocol — not clinically establishedCommunity guide
RouteSubcutaneous injection
FrequencyOnce daily
StartingFull dose from day one: 2 mg for research vials; "No titration required"
EscalationNone
Target2 mg daily for research vials, mirroring the original phase 3
CycleStandard 26 weeks, extended 52 weeks

Use for general "GH" purposes is off-label; the label figures apply only to HIV lipodystrophy.

Batches on file1
10 mgJA-102109 · 2026-0199.65%
Read with10
Cautions & interactions

Glucose intolerance/diabetes risk; fluid retention; contraindications per PI; not indicated for weight loss

Can raise glucose; monitor if on diabetes meds; fluid retention may affect BP/CHF; avoid with active malignancy (per clinical guidance).

CV 3 of 5 — Improves visceral fat in a specific indication; indirect cardiometabolic benefits; monitor glucose.